Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.53 |
| ▸ | STAT3 | P40763 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 2/20 | 0.50 |
| ▸ | CDK2 | P24941 | 2/20 | 0.50 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.50 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.49 |
| ▸ | WNT3A | P56704 | 3/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27750743 | 0.87 | KDM4E (0.62) | KDM4EYTHDC1STAT3HIF1ANPC1 | |
| SCHEMBL82761 | 0.87 | KDM4E (0.62) | KDM4EYTHDC1STAT3HIF1ANPC1 | |
| Hydrochloric Acid SCHEMBL5071439 | 0.86 | KDM4E (0.60) | KDM4EYTHDC1STAT3HIF1ANPC1 | |
| SCHEMBL28139037 | 0.86 | KDM4E (0.60) | KDM4EYTHDC1STAT3HIF1ANPC1 | |
| Hydrochloric Acid SCHEMBL30404733 | 0.86 | KDM4E (0.60) | KDM4EYTHDC1STAT3HIF1ANPC1 | |
| Hydrochloric Acid SCHEMBL29962256 | 0.86 | KDM4E (0.60) | KDM4EYTHDC1STAT3HIF1ANPC1 | |
| Hydrochloric Acid SCHEMBL2175299 | 0.86 | KDM4E (0.60) | KDM4EYTHDC1STAT3HIF1ANPC1 | |
| SCHEMBL5908296 | 0.84 | KDM4E (0.57) | CYP1A2KDM4EYTHDC1STAT3HIF1A | |
| Oxalic Acid SCHEMBL6033591 | 0.83 | FLT3 (0.58) | KDM4EYTHDC1STAT3HIF1ANPC1 | |
| SCHEMBL8067938 | 0.83 | CYP1A2 (0.54) | CYP1A2KDM4EYTHDC1STAT3HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911364-B2 | Positive allosteric modulators of GABAA receptor | PEPTICOM LTD. (IL) | 2024-02-27 | — | — | US | disclosed |
| US-20210353592-A1 | POSITIVE ALLOSTERIC MODULATORS OF GABAA RECEPTOR | PEPTICOM LTD. (IL) | 2021-11-18 | — | — | US | disclosed |
| US-20200283502-A1 | POSITIVE ALLOSTERIC MODULATORS OF GABA A RECEPTOR | PEPTICOM LTD. (IL) | 2020-09-10 | — | — | US | disclosed |
| WO-2020065642-A1 | POSITIVE ALLOSTERIC MODULATORS OF GABAA RECEPTOR | PEPTICOM LTD. (IL) | 2020-04-02 | — | — | WO | disclosed |
| WO-2019058349-A1 | POSITIVE ALLOSTERIC MODULATORS OF GABA A RECEPTOR | PEPTICOM LTD (IL) | 2019-03-28 | — | — | WO | disclosed |
| EP-1966158-B1 | SUBSTITUTED CINNOLINE DERIVATIVES AS GABAA-RECEPTOR MODULATORS AND METHOD FOR THEIR SYNTHESIS | ASTRAZENECA AB (SE) | 2012-08-08 | — | — | EP | disclosed |
| US-20110144331-A1 | Cinnoline Compounds for the Treatment of Anxiety, Cognitive and Mood Disorders | ASTRAZENECA AB (SE) | 2011-06-16 | — | — | US | disclosed |
| US-20100184738-A1 | Uses of cinnoline compounds to treat schizophrenia | ASTRAZENECA AB (SE) | 2010-07-22 | — | — | US | disclosed |
| EP-2167091-A1 | CINNOLINE COMPOUNDS FOR USE IN THE TREATMENT OF SCHIZOPHRENIA | AstraZeneca AB (SE) | 2010-03-31 | — | — | EP | disclosed |
| US-20090036454-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | US | disclosed |
| EP-1265873-A2 | 4-OXO-1,4-DIHYDRO-3-CINNOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| US-20020045619-A1 | 4-oxo-1,4-dihydro-3-cinnolinecarboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-04-18 | — | — | US | disclosed |
| US-20020045619-A1 | 4-oxo-1,4-dihydro-3-cinnolinecarboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-04-18 | — | — | US | disclosed |
| WO-2001070706-A2 | 4-OXO-1,4-DIHYDRO-3-CINNOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
| EP-0328282-B1 | PHARMACEUTICAL | ICI AMERICAS INC. (US) | 1992-08-19 | — | — | EP | disclosed |
| EP-0205272-B1 | CINNOLINE DERIVATIVES | ICI AMERICAS INC. (US) | 1991-08-14 | — | — | EP | disclosed |
| US-4925844-A | ADMINISTERING 4-AMINO-8-PHENYL-N-PROPYL-3-CINNOLINECARBOXAMIDE | ICI AMERICAS INC. (US) | 1990-05-15 | — | — | US | disclosed |
| US-4886800-A | Substituted cinnoline derivatives as CNS depressants | ICI AMERICAS INC. (US) | 1989-12-12 | — | — | US | disclosed |
| EP-0328282-A2 | Pharmaceutical | ICI AMERICAS INC. (US) | 1989-08-16 | — | — | EP | disclosed |
| EP-0205272-A2 | Cinnoline derivatives | ICI AMERICAS INC. (US) | 1986-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353592-A1 | POSITIVE ALLOSTERIC MODULATORS OF GABAA RECEPTOR | GABRP, GABRB2, GABRB1 | CYP1A2 1134/4885KDM4E 2877/4885YTHDC1 4832/4885 |
| US-11911364-B2 | Positive allosteric modulators of GABAA receptor | GABRP, GABRB2, GABRB1 | CYP1A2 1134/4885KDM4E 2877/4885YTHDC1 4832/4885 |
| US-20110144331-A1 | Cinnoline Compounds for the Treatment of Anxiety, Cognitive and Mood Disorders | HTR7, HTR2C, CRH | CYP1A2 455/4885KDM4E 3855/4885YTHDC1 4868/4885 |
| US-20020045619-A1 | 4-oxo-1,4-dihydro-3-cinnolinecarboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, EIF2AK2 | CYP1A2 1659/4885KDM4E 1153/4885YTHDC1 679/4885 |
| US-20200283502-A1 | POSITIVE ALLOSTERIC MODULATORS OF GABA A RECEPTOR | GABRB3, GABRB1, GABRB2 | CYP1A2 1785/4885KDM4E 570/4885YTHDC1 2288/4885 |
| US-20090036454-A1 | Compounds and Uses Thereof | MAPT, BDNF, PYGB | CYP1A2 428/4885KDM4E 3031/4885YTHDC1 4774/4885 |
| US-20100184738-A1 | Uses of cinnoline compounds to treat schizophrenia | COMT, BACE1, CHAT | CYP1A2 367/4885KDM4E 4245/4885YTHDC1 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.